2024-06-30false--12-312024Q2000175659400017565942024-01-012024-06-300001756594iva:LongTermFinancialDebtDerivativesMemberiva:WarrantAgreementWithEuropeanInvestmentBankMember2022-11-282022-11-280001756594iva:DavidNikodemMemberiva:Bsa20232ShareWarrantPlanMember2023-12-310001756594iva:DavidNikodemMemberiva:Bsa20231ShareWarrantPlanMember2023-12-310001756594iva:DavidNikodemMemberiva:BsaShareWarrantsMember2021-12-310001756594iva:DavidNikodemMemberiva:BsaShareWarrantsMember2020-12-310001756594iva:DavidNikodemMemberiva:BsaShareWarrantsMember2019-12-310001756594iva:ServiceProvidersMemberiva:BsaShareWarrantsMember2018-12-310001756594iva:DirectorsMemberiva:BsaShareWarrantsMember2017-12-310001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember2024-01-012024-06-300001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember2023-01-012023-12-310001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember2022-11-282022-11-280001756594ifrs-full:TopOfRangeMemberiva:Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember2024-05-162024-05-160001756594ifrs-full:BottomOfRangeMemberiva:Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember2024-05-162024-05-160001756594iva:WarrantAgreementWithEuropeanInvestmentBankMember2022-07-012022-07-010001756594iva:LongTermFinancialDebtDerivativesMemberiva:WarrantAgreementWithEuropeanInvestmentBankMember2022-07-010001756594iva:IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember2024-10-142024-10-140001756594iva:RoyaltyCertificatesLiabilitiesMember2024-01-012024-06-300001756594iva:LicensingAgreementWithHepalysMemberiva:HepalysPharmaIncMember2023-10-112023-10-110001756594iva:FinancingThroughFundRaisingMemberiva:LicensingAndCollaborationAgreementWithCttqMemberiva:ScenarioTwoMember2024-10-112024-10-110001756594iva:FinancingThroughFundRaisingMemberiva:LicensingAndCollaborationAgreementWithCttqMemberiva:ScenarioThreeMember2024-10-112024-10-110001756594iva:FinancingThroughFundRaisingMemberiva:LicensingAndCollaborationAgreementWithCttqMemberiva:ScenarioOneMember2024-10-112024-10-110001756594iva:FinanceContractWithEuropeanInvestmentBankMember2024-06-300001756594iva:PresentationOfResultsFromStudyMemberiva:Nativ3PhaseIiiClinicalTrialWithLanifibranorInPatientsWithMashNashMember2024-07-050001756594iva:LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember2022-01-012022-12-310001756594iva:LicensingAndCollaborationAgreementWithCttqMember2023-06-300001756594iva:ServiceContractWithAvantSanteMember2023-06-300001756594iva:LicensingAgreementWithHepalysMemberiva:HepalysPharmaIncMember2023-09-260001756594iva:Nativ3PhaseIiiTrialOfLanifibranorInNonCirrhoticNashMember2024-03-070001756594iva:FredericCrenMemberiva:LongTermIncentivePlanInPerformanceUnits2023Member2024-03-250001756594iva:HepalysPharmaIncMember2023-10-112023-10-110001756594iva:LongTermIncentivePlanInPerformanceUnitsMember2024-01-010001756594ifrs-full:BottomOfRangeMemberiva:PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember2024-05-160001756594iva:PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember2024-05-160001756594iva:LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember2024-03-180001756594iva:LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember2022-06-012022-06-300001756594iva:LoanAgreementsWithSyndicateOfFrenchBanksStateGuaranteedLoanPretGarantiParLetatMember2022-06-012022-06-300001756594iva:FinancingFromSyndicateOfFrenchBanksMember2022-06-012022-06-300001756594iva:FinancingAgreementInThreePhasesMember2024-01-012024-06-300001756594iva:FinanceContractWithEuropeanInvestmentBankMember2022-05-162022-05-160001756594iva:IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember2024-02-012024-02-010001756594iva:ContractCroWithPharmaceuticalResearchAssociatesB.vMember2024-06-300001756594iva:ContractCroWithPharmaceuticalResearchAssociatesB.vMember2023-12-310001756594iva:FinancingThroughFundRaisingMemberiva:LicensingAndCollaborationAgreementWithCttqMember2024-10-112024-10-110001756594iva:IssuanceOfRoyaltyCertificatesMember2024-07-182024-07-180001756594iva:IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember2023-01-012023-01-310001756594iva:IndicationOfContinuationOfRecruitmentForPhaseIiiTrialNativ3OfLanifibranorInNonCirrhoticNashashMember2022-01-012022-12-3100017565942024-01-012024-01-0100017565942023-01-012023-01-0100017565942019-01-012019-12-310001756594iva:LicensingAgreementWithHepalysMember2023-10-180001756594iva:FibroscanMachinesMemberifrs-full:TopOfRangeMember2024-01-012024-06-300001756594iva:FibroscanMachinesMemberifrs-full:BottomOfRangeMember2024-01-012024-06-300001756594ifrs-full:RightofuseAssetsMember2024-01-012024-06-300001756594ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2024-01-012024-06-300001756594ifrs-full:SharePremiumMember2024-01-012024-06-300001756594ifrs-full:IssuedCapitalMember2024-01-012024-06-300001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMemberiva:DrawdownOfBorrowingsMember2024-01-182024-01-180001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember2024-01-182024-01-180001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember2022-12-082022-12-080001756594iva:IssuanceOfSharesOrWarrantsSubjectToConditionsMember2024-10-142024-10-140001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMemberiva:WarrantAgreementWithEuropeanInvestmentBankMember2024-06-300001756594ifrs-full:OrdinarySharesMemberiva:WarrantAgreementWithEuropeanInvestmentBankMember2023-12-310001756594iva:IssuanceOfSharesOrWarrantsSubjectToConditionsMember2024-10-140001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMemberiva:LongTermFinancialDebtDerivativesMemberiva:WarrantAgreementWithEuropeanInvestmentBankMember2024-01-040001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember2024-01-030001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMemberiva:LongTermFinancialDebtDerivativesMemberiva:WarrantAgreementWithEuropeanInvestmentBankMember2022-11-280001756594iva:EquityRecoveryLoansMember2023-05-012023-05-310001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember2024-06-300001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember2024-06-300001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember2024-01-040001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember2023-12-310001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember2022-11-280001756594iva:PhaseIiClinicalTrialEvaluatingPlaceboInPatientsWithMashNashAndT2dMember2024-03-182024-03-180001756594iva:PhaseIiClinicalTrialEvaluatingLanifibranorInPatientsWithT2dAndNonalcoholicFattyLiverDiseaseMember2024-03-182024-03-180001756594iva:LegendPhaseIiaCombinationTrialWithLanifibranorAndEmpagliflozinInPatientsWithMashNashAndT2dMember2024-03-182024-03-180001756594iva:ChiaTaiTianqingMember2024-06-300001756594iva:ContractCroWithResearchAssociatesGroupeB.vMember2021-04-300001756594ifrs-full:TopOfRangeMemberiva:PharmaceuticalResearchAssociatesMember2024-01-012024-06-300001756594ifrs-full:BottomOfRangeMemberiva:PharmaceuticalResearchAssociatesMember2024-01-012024-06-300001756594iva:WarrantAgreementWithEuropeanInvestmentBankMember2024-01-042024-01-040001756594iva:LongTermFinancialDebtDerivativesMemberiva:WarrantAgreementWithEuropeanInvestmentBankMember2022-07-012022-07-010001756594iva:IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember2024-10-142024-10-140001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMemberiva:LongTermFinancialDebtDerivativesMemberiva:WarrantAgreementWithEuropeanInvestmentBankMember2024-01-042024-01-040001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMemberiva:LongTermFinancialDebtDerivativesMemberiva:WarrantAgreementWithEuropeanInvestmentBankMember2022-11-282022-11-280001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember2024-01-032024-01-030001756594iva:IssuanceOfRoyaltyCertificatesMember2024-07-180001756594iva:LicensingAndCollaborationAgreementWithCttqMember2024-01-182024-01-180001756594iva:FinancingAgreementInThreePhasesMember2024-06-300001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember2024-01-180001756594iva:Bsa2024Member2024-06-300001756594iva:Bsa2022Member2024-06-300001756594iva:DavidNikodemMemberiva:Bsa20232ShareWarrantPlanMember2023-01-012023-12-310001756594iva:DavidNikodemMemberiva:Bsa20231ShareWarrantPlanMember2023-01-012023-12-310001756594ifrs-full:NotLaterThanThreeMonthsMember2024-06-300001756594ifrs-full:NotLaterThanThreeMonthsMember2023-12-310001756594iva:LaterThanTwoMonthsMember2024-06-300001756594ifrs-full:NotLaterThanOneMonthMember2024-06-300001756594ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember2024-06-300001756594ifrs-full:NotLaterThanOneMonthMember2023-12-310001756594ifrs-full:LaterThanOneMonthAndNotLaterThanTwoMonthsMember2023-12-3100017565942024-01-012024-12-310001756594iva:RoyaltyCertificatesLiabilitiesMemberifrs-full:DiscountRateMeasurementInputMember2024-06-300001756594iva:FinancingFromSyndicateOfFrenchBanksMember2024-01-012024-06-300001756594iva:InventivaIncMember2024-01-012024-06-300001756594iva:HepalysPharmaIncMember2024-01-012024-06-300001756594iva:HepalysPharmaIncMember2023-01-012023-12-310001756594ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2024-06-300001756594ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2023-12-310001756594iva:HepalysPharmaIncMember2024-01-152024-01-150001756594iva:FinanceContractWithEuropeanInvestmentBankMember2024-01-182024-01-180001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember2024-01-042024-01-040001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember2024-01-012024-06-300001756594iva:FinancingFromSyndicateOfFrenchBanksMember2020-05-012020-05-310001756594iva:IssuanceOfSharesWithoutPreferentialSubscriptionRightsMember2024-10-140001756594iva:IssuanceOfSharesOrWarrantsWithoutPreferentialSubscriptionRightsMember2024-10-140001756594ifrs-full:IssuedCapitalMember2024-03-250001756594iva:LicensingAndCollaborationAgreementWithCttqMember2023-12-310001756594iva:HepalysPharmaIncMember2023-01-012023-12-310001756594iva:NewBonusShareAwardPlan20232Member2024-06-300001756594iva:NewBonusShareAwardPlan20231Member2024-06-300001756594iva:Bsa20232ShareWarrantPlanMember2024-06-300001756594iva:Bsa20231ShareWarrantPlanMember2024-06-300001756594iva:BonusShareAwardPlansMember2024-06-300001756594iva:NewShareWarrantPlansBsa2019TerMember2023-12-310001756594iva:NewShareWarrantPlansBsa2019Member2023-12-310001756594iva:NewShareWarrantPlansBsa2019BisMember2023-12-310001756594iva:NewBsa2021ShareWarrantPlanMember2023-12-310001756594iva:NewBonusShareAwardPlanAga2021BisMember2023-12-310001756594iva:NewBonusShareAwardPlanAga20211Member2023-12-310001756594iva:NewBonusShareAwardPlan20232Member2023-12-310001756594iva:NewBonusShareAwardPlan20231Member2023-12-310001756594iva:LongTermIncentivePlanInPerformanceUnitsMember2023-12-310001756594iva:LongTermIncentivePlanInPerformanceUnits2023Member2023-12-310001756594iva:BspcePlansMember2023-12-310001756594iva:BspceAndBsaShareWarrantsMember2023-12-310001756594iva:Bspce2021PlanMember2023-12-310001756594iva:BsaPlansMember2023-12-310001756594iva:Bsa20232ShareWarrantPlanMember2023-12-310001756594iva:Bsa20231ShareWarrantPlanMember2023-12-310001756594iva:Bsa2018PlanMember2023-12-310001756594iva:Bsa2017PlanMember2023-12-310001756594iva:BonusShareAwardPlansMember2023-12-310001756594iva:NewBonusShareAwardPlan20232Member2024-01-012024-06-300001756594iva:LongTermIncentivePlanInPerformanceUnitsMember2024-01-012024-06-300001756594iva:FredericCrenMemberiva:LongTermIncentivePlanInPerformanceUnits2023Member2024-03-252024-03-250001756594iva:NewBonusShareAwardPlanAga2021BisMember2024-01-012024-06-300001756594iva:NewBonusShareAwardPlanAga20211Member2024-01-012024-06-300001756594iva:NewShareWarrantPlansBsa2019TerMember2024-06-300001756594iva:NewShareWarrantPlansBsa2019Member2024-06-300001756594iva:NewShareWarrantPlansBsa2019BisMember2024-06-300001756594iva:NewBsa2021ShareWarrantPlanMember2024-06-300001756594iva:BspcePlansMember2024-06-300001756594iva:BspceAndBsaShareWarrantsMember2024-06-300001756594iva:Bspce2021PlanMember2024-06-300001756594iva:BsaPlansMember2024-06-300001756594iva:Bsa2018PlanMember2024-06-300001756594iva:Bsa2017PlanMember2024-06-300001756594iva:Bsa2024Member2024-01-012024-06-300001756594iva:Bsa2022Member2024-01-012024-06-300001756594iva:BonusShareAwardPlansMember2024-01-012024-06-300001756594iva:InventivaS.aMember2024-06-300001756594iva:InventivaIncMember2024-06-300001756594iva:InventivaS.aMember2023-06-300001756594iva:InventivaIncMember2023-06-300001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2024-01-1800017565942024-01-180001756594iva:LoanAgreementsWithSyndicateOfFrenchBanksUnderStimulusEconomicPlanMember2022-06-300001756594iva:FinanceContractWithEuropeanInvestmentBankMember2022-05-160001756594iva:InventivaIncMember2024-06-300001756594ifrs-full:SharePremiumMember2024-03-252024-03-250001756594ifrs-full:IssuedCapitalMember2024-03-252024-03-250001756594ifrs-full:AccumulatedImpairmentMember2024-06-300001756594ifrs-full:AccumulatedImpairmentMember2023-12-310001756594iva:FinanceContractWithEuropeanInvestmentBankMember2024-01-012024-06-300001756594ifrs-full:GrossCarryingAmountMember2024-06-300001756594ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2024-06-300001756594ifrs-full:GrossCarryingAmountMember2023-12-310001756594ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-12-310001756594iva:Aga2021Aga2021BisMember2024-01-012024-06-3000017565942024-03-252024-03-250001756594iva:InventivaIncMember2024-01-012024-06-300001756594iva:HepalysPharmaIncMember2024-06-300001756594iva:HepalysPharmaIncMember2023-12-310001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMemberifrs-full:FinancialLiabilitiesAtFairValueMember2024-06-300001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMemberifrs-full:FinancialLiabilitiesAtFairValueMember2024-06-300001756594ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberiva:LongTermFinancialDebtDerivativesMemberifrs-full:Level3OfFairValueHierarchyMember2024-06-300001756594ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberifrs-full:ShorttermBorrowingsMember2024-06-300001756594ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberifrs-full:LongtermBorrowingsMember2024-06-300001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:Level3OfFairValueHierarchyMember2024-06-300001756594iva:TradePayablesMember2024-06-300001756594iva:RoyaltyCertificatesLiabilitiesMember2024-06-300001756594iva:OtherMiscellaneousPayablesMember2024-06-300001756594iva:DerivativeInstrumentsMember2024-06-300001756594ifrs-full:ShorttermBorrowingsMember2024-06-300001756594ifrs-full:LongtermBorrowingsMember2024-06-300001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2024-06-300001756594ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberiva:LongTermFinancialDebtDerivativesMemberifrs-full:Level3OfFairValueHierarchyMember2023-12-310001756594ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMemberifrs-full:Level3OfFairValueHierarchyMember2023-12-310001756594ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberiva:TradePayablesMember2023-12-310001756594ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberiva:RoyaltyCertificatesLiabilitiesMember2023-12-310001756594ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberiva:OtherMiscellaneousPayablesMember2023-12-310001756594ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberifrs-full:ShorttermBorrowingsMember2023-12-310001756594ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMemberifrs-full:LongtermBorrowingsMember2023-12-310001756594ifrs-full:FinancialAssetsAtAmortisedCostCategoryMemberiva:DerivativeInstrumentsMember2023-12-310001756594iva:TradePayablesMember2023-12-310001756594iva:RoyaltyCertificatesLiabilitiesMember2023-12-310001756594iva:OtherMiscellaneousPayablesMember2023-12-310001756594iva:DerivativeInstrumentsMember2023-12-310001756594ifrs-full:ShorttermBorrowingsMember2023-12-310001756594ifrs-full:LongtermBorrowingsMember2023-12-310001756594ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2023-12-310001756594ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2023-12-310001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberiva:OtherReceivablesMember2024-06-300001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberiva:IfrsCashAndCashEquivalentsMember2024-06-300001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberiva:AdvancePaymentMember2024-06-300001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberiva:AccruedIncomeMember2024-06-300001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:TradeReceivablesMember2024-06-300001756594iva:OtherReceivablesMember2024-06-300001756594iva:IfrsCashAndCashEquivalentsMember2024-06-300001756594iva:AdvancePaymentMember2024-06-300001756594iva:AccruedIncomeMember2024-06-300001756594ifrs-full:TradeReceivablesMember2024-06-300001756594ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2024-06-300001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberiva:ShortTermDepositAccountsMember2023-12-310001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberiva:OtherReceivablesMember2023-12-310001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberiva:LongTermSecurityDepositsMember2023-12-310001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberiva:LongTermDepositAccountsMember2023-12-310001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberiva:IfrsCashAndCashEquivalentsMember2023-12-310001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberiva:AdvancePaymentMember2023-12-310001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMemberifrs-full:TradeReceivablesMember2023-12-310001756594iva:ShortTermDepositAccountsMember2023-12-310001756594iva:OtherReceivablesMember2023-12-310001756594iva:LongTermSecurityDepositsMember2023-12-310001756594iva:LongTermDepositAccountsMember2023-12-310001756594iva:IfrsCashAndCashEquivalentsMember2023-12-310001756594iva:AdvancePaymentMember2023-12-310001756594ifrs-full:TradeReceivablesMember2023-12-310001756594ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2023-12-310001756594iva:NewBonusShareAwardPlan20231Member2023-01-012023-06-300001756594iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember2024-06-300001756594ifrs-full:SharePremiumMember2024-06-300001756594ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2024-06-300001756594ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-06-300001756594ifrs-full:IssuedCapitalMember2024-06-300001756594iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember2023-12-310001756594ifrs-full:SharePremiumMember2023-12-310001756594ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2023-12-310001756594ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-12-310001756594ifrs-full:IssuedCapitalMember2023-12-310001756594iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember2023-06-300001756594ifrs-full:SharePremiumMember2023-06-300001756594ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2023-06-300001756594ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-06-300001756594ifrs-full:IssuedCapitalMember2023-06-300001756594iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember2022-12-310001756594iva:HepalysPharmaIncMember2022-12-310001756594ifrs-full:SharePremiumMember2022-12-310001756594ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2022-12-310001756594ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-12-310001756594ifrs-full:IssuedCapitalMember2022-12-310001756594iva:IfrsSalesAndMarketingExpenseMember2024-01-012024-06-300001756594iva:IfrsResearchAndDevelopmentExpenseMember2024-01-012024-06-300001756594iva:IfrsGeneralAndAdministrativeExpenseMember2024-01-012024-06-300001756594iva:IfrsSalesAndMarketingExpenseMember2023-01-012023-06-300001756594iva:IfrsResearchAndDevelopmentExpenseMember2023-01-012023-06-300001756594iva:IfrsGeneralAndAdministrativeExpenseMember2023-01-012023-06-300001756594iva:NewBonusShareAwardPlan20231Member2024-01-012024-06-300001756594iva:LongTermIncentivePlanInPerformanceUnits2023Member2024-01-012024-06-300001756594iva:BspceAndBsaShareWarrantsMember2024-01-012024-06-300001756594iva:LicensingAndCollaborationAgreementWithCttqMember2024-06-300001756594iva:PharmaceuticalResearchAssociatesMember2024-06-300001756594iva:ContractManufacturingOrganizationsMember2024-06-300001756594iva:ContractCroWithResearchAssociatesGroupeB.vMember2024-06-300001756594iva:ClinicalTrialsMember2024-06-300001756594ifrs-full:OtherContingentLiabilitiesMember2024-06-300001756594ifrs-full:LeaseLiabilitiesMember2024-06-300001756594iva:ContractManufacturingOrganizationsMember2023-12-310001756594iva:ClinicalTrialsMember2023-12-310001756594ifrs-full:OtherContingentLiabilitiesMember2023-12-310001756594ifrs-full:LeaseLiabilitiesMember2023-12-310001756594iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember2024-01-012024-06-300001756594iva:HepalysPharmaIncMember2024-01-012024-06-300001756594ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2024-01-012024-06-300001756594ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2024-01-012024-06-300001756594iva:RetainedEarningsExcludingProfitLossFromCurrentReportingPeriodAndTreasurySharesMember2023-01-012023-06-300001756594ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2023-01-012023-06-300001756594ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-01-012023-06-3000017565942023-06-300001756594ifrs-full:LeaseLiabilitiesMemberifrs-full:TopOfRangeMember2024-06-300001756594ifrs-full:LeaseLiabilitiesMemberifrs-full:BottomOfRangeMember2024-06-300001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMemberiva:DrawdownOfBorrowingsMember2024-01-180001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMember2024-01-180001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMember2022-12-080001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2024-06-300001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2024-06-300001756594iva:RoyaltyCertificatesLiabilitiesMember2024-06-300001756594ifrs-full:NotLaterThanOneYearMember2024-06-300001756594ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2024-06-300001756594ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2024-06-300001756594ifrs-full:LaterThanFiveYearsMember2024-06-300001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2023-12-310001756594iva:RoyaltyCertificatesLiabilitiesMember2023-12-310001756594ifrs-full:NotLaterThanOneYearMember2023-12-310001756594ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2023-12-310001756594ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2023-12-310001756594ifrs-full:LaterThanFiveYearsMember2023-12-310001756594iva:RoyaltyCertificateLiabilitiesMember2023-08-3100017565942022-12-310001756594iva:FinanceContractWithEuropeanInvestmentBankSecondTrancheMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2024-01-182024-01-180001756594iva:FinanceContractWithEuropeanInvestmentBankFirstTrancheMemberifrs-full:FinancialLiabilitiesAtAmortisedCostMember2024-01-012024-06-3000017565942023-01-012023-12-310001756594iva:HepalysPharmaIncMember2024-06-300001756594iva:HepalysPharmaIncMember2023-12-3100017565942023-12-3100017565942023-01-012023-06-300001756594iva:FibroscanMachinesMember2024-01-012024-06-3000017565942024-06-30iva:itemiva:entityiva:trancheiva:loaniva:agreementiva:planiva:siteiso4217:JPYxbrli:sharesiva:Diso4217:EURxbrli:sharesiso4217:EURiso4217:USDiso4217:USDiso4217:EURiso4217:EURxbrli:sharesxbrli:pureiso4217:USDiva:employeeutr:g
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of October 2024
Commission File Number: 001-39374
Inventiva S.A.
(Translation of registrant’s name into English)
50 rue de Dijon
21121 Daix France
+33 3 80 44 75 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On October 14, 2024, the Registrant issued the Interim Financial Report for the Six Months Ended June 30, 2024 (the “Interim Financial Report”). A copy of the Interim Financial Report is attached to this Report as exhibit 99.1.
EXHIBIT INDEX
| | |
Exhibit
No. | | Description |
99.1 | | Interim Financial Report |
101.INS XBRL | | Instance Document. |
101.SCH XBRL | | Taxonomy Extension Schema Document. |
101.CAL XBRL | | Taxonomy Extension Calculation Linkbase Document. |
101.DEF XBRL | | Taxonomy Extension Definition Linkbase Document. |
101.IAB XBRL | | Taxonomy Extension Labels Linkbase Document. |
101.PRE XBRL | | Taxonomy Extension Presentation Linkbase Document |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | Inventiva S.A. |
| | (Registrant) |
| | |
Date: October 15, 2024 | | /s/ Frédéric Cren |
| | Frédéric Cren |
| | Chief Executive Officer |
